THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY

Objective: Immune thrombocytopenic purpura (ITP) is the most common cause of pediatric thrombocytopenia. It is usually a self-limiting disease; however, 20-30% of cases become chronic. In this study, we aimed to investigate pediatric ITP cases’ outcomes and whether there are any factors affecting ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barış YILMAZ, Ahmet KOÇ, Ömer DOĞRU, Burcu TUFAN TAŞ, Rabia Emel ŞENAY, Nurşah EKER, Ayşe Gülnur TOKUÇ
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/05bfc6f50a7a4283a7730fc55aded722
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05bfc6f50a7a4283a7730fc55aded722
record_format	dspace
spelling	oai:doaj.org-article:05bfc6f50a7a4283a7730fc55aded7222021-11-10T04:33:10ZTHE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY2531-137910.1016/j.htct.2021.10.985https://doaj.org/article/05bfc6f50a7a4283a7730fc55aded7222021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011329https://doaj.org/toc/2531-1379Objective: Immune thrombocytopenic purpura (ITP) is the most common cause of pediatric thrombocytopenia. It is usually a self-limiting disease; however, 20-30% of cases become chronic. In this study, we aimed to investigate pediatric ITP cases’ outcomes and whether there are any factors affecting chronicity. Methodology: We analyzed retrospectively our 184 newly diagnosed pediatric ITP cases. Thrombocytopenia was defined as chronic ITP if it persists after 12 months. We evaluated the role of clinical and laboratory findings of patients and treatment modalities in the chronicity of ITP. Results: The mean age of patients was 5.4 ± 4.75 years at diagnosis. As first-line treatment, 87 (47.3%) of patients were given Intravenous Immune Globulin, 65 (35.3%) of patients were given methylprednisolone, and 32 (17.4%) of patients were followed without any medication. Chronic ITP developed in 39 patients (21.1%). Chronic ITP development rate was 20.19% in boys and 22.5% in girls (p=0.7). While the chronicity rate was 7.02% in children younger than two years old and 17.81% in children between 2 and 6 years, it was 42.59% in children older than six years old (p<0.0001). Mean hemoglobin and absolute lymphocyte count were significantly lower in chronic ITP patients in the 2-6 years age group. (p=0.014 and p=0.048, respectively). The first-line treatment choice had no important effect on chronicity (p=0.61). Conclusion: Our results suggest that the most critical factor in developing chronic ITP was the age at diagnosis. Low lymphocyte counts at diagnosis may be associated with a high chronicity ratio.Barış YILMAZAhmet KOÇÖmer DOĞRUBurcu TUFAN TAŞRabia Emel ŞENAYNurşah EKERAyşe Gülnur TOKUÇElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S22- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Barış YILMAZ Ahmet KOÇ Ömer DOĞRU Burcu TUFAN TAŞ Rabia Emel ŞENAY Nurşah EKER Ayşe Gülnur TOKUÇ THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
description	Objective: Immune thrombocytopenic purpura (ITP) is the most common cause of pediatric thrombocytopenia. It is usually a self-limiting disease; however, 20-30% of cases become chronic. In this study, we aimed to investigate pediatric ITP cases’ outcomes and whether there are any factors affecting chronicity. Methodology: We analyzed retrospectively our 184 newly diagnosed pediatric ITP cases. Thrombocytopenia was defined as chronic ITP if it persists after 12 months. We evaluated the role of clinical and laboratory findings of patients and treatment modalities in the chronicity of ITP. Results: The mean age of patients was 5.4 ± 4.75 years at diagnosis. As first-line treatment, 87 (47.3%) of patients were given Intravenous Immune Globulin, 65 (35.3%) of patients were given methylprednisolone, and 32 (17.4%) of patients were followed without any medication. Chronic ITP developed in 39 patients (21.1%). Chronic ITP development rate was 20.19% in boys and 22.5% in girls (p=0.7). While the chronicity rate was 7.02% in children younger than two years old and 17.81% in children between 2 and 6 years, it was 42.59% in children older than six years old (p<0.0001). Mean hemoglobin and absolute lymphocyte count were significantly lower in chronic ITP patients in the 2-6 years age group. (p=0.014 and p=0.048, respectively). The first-line treatment choice had no important effect on chronicity (p=0.61). Conclusion: Our results suggest that the most critical factor in developing chronic ITP was the age at diagnosis. Low lymphocyte counts at diagnosis may be associated with a high chronicity ratio.
format	article
author	Barış YILMAZ Ahmet KOÇ Ömer DOĞRU Burcu TUFAN TAŞ Rabia Emel ŞENAY Nurşah EKER Ayşe Gülnur TOKUÇ
author_facet	Barış YILMAZ Ahmet KOÇ Ömer DOĞRU Burcu TUFAN TAŞ Rabia Emel ŞENAY Nurşah EKER Ayşe Gülnur TOKUÇ
author_sort	Barış YILMAZ
title	THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
title_short	THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
title_full	THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
title_fullStr	THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
title_full_unstemmed	THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY
title_sort	outcome of immune thrombocytopenic purpura in childhood and the risk factors for chronicity
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/05bfc6f50a7a4283a7730fc55aded722
work_keys_str_mv	AT barısyilmaz theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT ahmetkoc theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT omerdogru theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT burcutufantas theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT rabiaemelsenay theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT nursaheker theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT aysegulnurtokuc theoutcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT barısyilmaz outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT ahmetkoc outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT omerdogru outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT burcutufantas outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT rabiaemelsenay outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT nursaheker outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity AT aysegulnurtokuc outcomeofimmunethrombocytopenicpurpurainchildhoodandtheriskfactorsforchronicity
_version_	1718440620995903488

THE OUTCOME OF IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDHOOD AND THE RISK FACTORS FOR CHRONICITY

Ejemplares similares